Mr has made over 1 trades of the Zomedica Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 62,996 units of ZOM stock worth $138,591 on 29 March 2018.
The largest trade he's ever made was exercising 62,996 units of Zomedica Pharmaceuticals stock on 29 March 2018 worth over $138,591. On average, Mr trades about 20,999 units every 0 days since 2018. As of 29 March 2018 he still owns at least 62,996 units of Zomedica Pharmaceuticals stock.
You can see the complete history of Mr Herbst stock trades at the bottom of the page.
Bruk Herbst is the Chief Commercial Officer at Zomedica Pharmaceuticals.
As the Chief Commercial Officer of Zomedica Pharmaceuticals, the total compensation of Mr Herbst at Zomedica Pharmaceuticals is $208,966. There are 1 executives at Zomedica Pharmaceuticals getting paid more, with Dr. Stephanie Laine Morley D.V.M., DVM having the highest compensation of $282,703.
Mr Herbst is 51, he's been the Chief Commercial Officer of Zomedica Pharmaceuticals since . There are 6 older and 6 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.
Bruk's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR, MI, 48108.
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers a Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include: